Clinical Chemistry Test Guide

ALT Blood Test (Alanine Aminotransferase)

Understanding Alanine Aminotransferase from liver-cell injury and blood sample collection to analyser measurement, Biomedical Scientist review and clinical decision-making.

Quick Facts

Alanine Aminotransferase (ALT) is a Clinical Chemistry enzyme test used mainly to support assessment of hepatocellular injury. It is interpreted with the patient’s clinical history, medication history, sample quality, local reference interval and wider liver-test pattern.

BiomarkerAlanine Aminotransferase
Also known asALT / ALAT / formerly SGPT
Main tissue associationLiver hepatocytes
DepartmentClinical Chemistry
SampleSerum or validated plasma
MethodIFCC-type enzymatic method
MeasurementNADH decrease at 340 nm
Reporting unitU/L
Reference intervalMethod and laboratory dependent
Educational scope: this guide explains laboratory medicine principles. It does not replace local laboratory SOPs, manufacturer instructions, clinical guidelines or medical advice.

Important distinction

ALT is primarily a marker of hepatocellular injury; it is not a direct measure of liver function.

An increased ALT activity may indicate injury or inflammation affecting hepatocytes, but ALT alone cannot identify the cause or determine overall liver function. Results should be interpreted alongside other laboratory findings, clinical information and the patient’s history.

Clinical Significance

ALT is an intracellular aminotransferase enzyme. In routine clinical practice it is requested as part of a liver profile or wider biochemical screen to help identify, monitor or investigate patterns of liver-cell injury. ALT activity in blood usually remains low when hepatocyte membranes are intact. When hepatocytes are injured, enzyme leakage into the circulation can increase measured ALT activity.

ALT is often described as more liver-associated than AST, although it is not completely liver-specific. Small amounts are found in other tissues, and clinical interpretation must take account of symptoms, medication, alcohol intake, metabolic risk factors, viral hepatitis risk, muscle injury, pregnancy context and other biochemical results.

Common clinical usesAssessing hepatocellular injury

ALT contributes to recognising hepatocellular patterns, especially when compared with AST, ALP, GGT and bilirubin.

MonitoringDisease and treatment trends

Serial ALT results may support monitoring of chronic liver disease, medication effects, metabolic dysfunction-associated steatotic liver disease (MASLD) and recovery after acute injury.

Key interpretation principle: ALT is a marker, not a diagnosis. The same ALT result may mean different things in different patients.

What is ALT?

ALT participates in amino acid metabolism by catalysing transfer of an amino group between alanine and 2-oxoglutarate. In liver-cell injury, intracellular ALT can leak into the blood and become measurable in serum or plasma.

ALT in context

ALT is clinically useful because it links biochemistry, hepatocyte integrity and laboratory measurement.

1Healthy hepatocytesALT is retained inside liver cells.
2Cell injuryMembrane integrity is disrupted.
3ALT leaks outEnzyme enters the bloodstream.
4Blood sampleALT activity is present in serum/plasma.
5Laboratory testThe analyser calculates enzyme activity.

Learning point

ALT is interpreted with the full liver-test pattern and local clinical pathway.

Principle of the Assay

Many modern Clinical Chemistry ALT methods use an IFCC-type enzymatic approach. ALT catalyses a transamination reaction, and a coupled LDH reaction allows the analyser to monitor NADH oxidation by measuring the decrease in absorbance at 340 nm.

L-Alaninesubstrate
2-Oxoglutarateco-substrate
ALTenzyme activity
Pyruvatereaction product
LDH
LDHcoupled enzyme
L-Lactatereaction product
NADHNAD+
NADH oxidationNADH to NAD+
ALT Activitycalculated rate
Enzymatic reaction

ALT transfers an amino group from alanine to 2-oxoglutarate, forming pyruvate and glutamate under assay conditions.

Why absorbance decreases

Pyruvate is converted to lactate by LDH while NADH is oxidised to NAD+. NADH absorbs at 340 nm, so absorbance falls as the reaction proceeds.

Activity calculation

The analyser measures the rate of absorbance decrease and converts this rate into ALT activity, typically reported in U/L.

Example laboratory implementation: Abbott Alinity c

Laboratory analysers may implement the underlying ALT methodology using manufacturer-specific reagents, calibration, reaction parameters, analytical measurement ranges and interference specifications.

Always refer to the current manufacturer’s Instructions for Use and locally validated laboratory procedures for analyser-specific requirements.

Laboratory Workflow

An ALT result is not just a number. It travels through pre-analytical, analytical and post-analytical stages before it reaches a clinical decision.

1
Patient

Patient attends GP, clinic, ward or emergency setting.

2
Collection

Blood collected into a locally validated tube.

3
Transport

Specimen transported according to local policy.

4
Reception

Request, identity and sample suitability checked.

5
Centrifugation

Serum or plasma separated for analysis.

6
Analysis

ALT measured on validated chemistry analyser.

7
Quality Control Status

The relevant quality-control status must be acceptable in accordance with the laboratory’s quality-control procedures before associated patient results are released.

8
Technical Validation / BMS Review

Depending on autoverification rules, analyser flags, delta checks and clinical significance, results may be automatically authorised or require Biomedical Scientist review.

9
Authorisation

Result released according to governance rules.

10
Decision

Clinician interprets result with patient context.

Specimen Requirements

Sample typeSerum or plasma may be suitable depending on the analytical method and laboratory procedure.
CollectionUse the specimen type and collection tube approved by the testing laboratory.
PreparationSamples may require centrifugation and separation before analysis according to laboratory procedures.
Transport and storageSample transport, storage and stability requirements are method dependent. Laboratories should follow the current manufacturer’s Instructions for Use and locally validated procedures.
Sample quality: haemolysis, lipaemia, icterus or other sample issues may influence measurement depending on the method and degree of interference.

Assay Limitations Across the Total Testing Process

Reliable ALT results depend on the complete testing pathway. The following Green, Amber and Red labels are supported by descriptive text and do not rely on colour alone.

Green — pre-analytical checks

  • Correct patient identification
  • Approved specimen type and collection tube
  • Appropriate transport and processing
  • Acceptable sample integrity

Amber — post-analytical review

  • Unexpected result or significant delta change
  • Comparison with previous results
  • Interpretation with other liver blood tests
  • Technical validation and appropriate escalation

Red — analytical concern

  • Unacceptable analyser or interference flag
  • Calibration, reagent or instrument concern
  • IQC outside laboratory acceptance criteria
  • Result outside the analytical measurement range
Why haemolysis matters: potential interference depends on the analytical method and degree of haemolysis. Reporting, rejection or commenting must follow analyser indices, manufacturer information and local procedure.

Quality Assurance

Quality assurance protects patients by ensuring that the ALT result is analytically valid before it is used clinically.

CalibrationLinks instrument response to the validated analytical system and method requirements.
IQCInternal quality control monitors the analytical system during routine testing.
Statistical QC reviewControl results are assessed using laboratory-defined quality-control procedures to identify imprecision, shifts, trends or other evidence of analytical instability. Westgard rules are one possible framework.
EQAExternal quality assessment provides independent assessment of analytical performance and comparison with appropriate peer groups or assigned values.
Method verificationPrecision, bias, reportable range and interference claims should be verified before method use.
Result validation and authorisationDepending on local rules, valid results may be automatically authorised or require technical validation by a Biomedical Scientist or other authorised laboratory professional.

Result Interpretation

ALT is a marker, not a diagnosis.

Interpretation should consider the degree of elevation, previous results and trend, AST, ALP, GGT, bilirubin, albumin where relevant, other laboratory results, medicines, alcohol history, metabolic risk factors, symptoms and clinical history. The magnitude of ALT elevation does not necessarily correspond directly to the severity of liver disease. A normal ALT result does not completely exclude liver disease.

Within intervalMildly raisedModerately raisedMarkedly raised
Within local reference interval

A result within the laboratory interval may be reassuring, but it does not exclude all liver disease. Clinical context remains important.

Mild ALT elevation

Mild elevation may be seen with metabolic dysfunction-associated steatotic liver disease (MASLD), medication effects, alcohol-related disease, viral hepatitis, recent strenuous exercise or other clinical contexts. Repeating the test or adding further investigations depends on local pathways.

Marked ALT elevation

Marked elevation may suggest significant hepatocellular injury and requires clinical correlation. Urgency depends on symptoms, bilirubin, coagulation, renal function, medication/toxin history and local escalation criteria.

ALT compared with AST

ALT and AST patterns can support interpretation, but ratios are not diagnostic in isolation. Muscle injury, alcohol-related disease, advanced liver disease and acute hepatocellular injury can alter the pattern.

Biomedical Scientist Insight

When assessing an unexpected ALT result, a Biomedical Scientist may consider patient identification, specimen integrity, analyser flags and reaction data, the analytical measurement range, repeat or dilution requirements, calibration and IQC status, previous results, related biochemical tests, significant changes, laboratory procedures and whether escalation is required.

Technical validity

The analyser result is assessed against flags, indices, quality-control status and local rules before release.

Professional contribution

Biomedical Scientists help ensure reliable laboratory results; they do not make the patient’s medical diagnosis.

Clinical Case

This is a fictional educational example and must not be used for individual clinical diagnosis.

Fictional resultsLiver blood test pattern
  • ALT: 186 U/L — increased
  • ALP: within reference interval
  • Bilirubin: within reference interval
  • GGT: mildly increased
  • Albumin: within reference interval
QuestionWhich biochemical pattern is most evident?

Consider the relative change in ALT compared with ALP.

Reveal learning point

The disproportionate increase in ALT compared with ALP is more consistent with a predominantly hepatocellular enzyme pattern than a cholestatic enzyme pattern. The laboratory pattern does not identify the underlying cause; clinical history, additional investigations and the wider laboratory picture are required.

ALT in Plain English

ALT is an enzyme found mainly inside liver cells. When liver cells become damaged or inflamed, more ALT can enter the bloodstream. Measuring ALT can therefore help healthcare professionals investigate possible liver-cell injury. However, an increased ALT result does not identify the cause by itself and should be interpreted alongside other laboratory results, symptoms and clinical information.

Frequently Asked Questions

What does ALT measure?

ALT testing measures enzyme activity in serum or plasma. Increased activity can occur when hepatocytes release intracellular enzyme into the blood.

Does high ALT always mean liver disease?

No. ALT is associated with hepatocellular injury, but it is not a diagnosis by itself. Medication, alcohol, metabolic risk factors, viral hepatitis, muscle injury and other clinical contexts may need consideration.

Can exercise affect ALT?

Strenuous exercise may affect some liver and muscle-related enzymes. Interpretation should include history and other test results, especially AST and creatine kinase if muscle injury is suspected.

How is ALT measured in the laboratory?

Many methods use an enzymatic reaction coupled to NADH oxidation. The analyser monitors a decrease in absorbance at 340 nm and calculates ALT activity from the reaction rate.

Why do reference intervals differ between laboratories?

Reference intervals depend on method, analyser, population, verification process and local governance. Always use the interval supplied with the patient result.

ALT: Key Revision Points

  • ALT is an enzyme found predominantly in hepatocytes.
  • Increased ALT activity commonly reflects hepatocellular injury.
  • ALT is not a direct measurement of overall liver function.
  • Many routine ALT methods use an LDH-coupled reaction involving NADH measurement around 340 nm.
  • Sample quality, analyser performance, calibration and QC affect result reliability.
  • ALT must be interpreted with other liver blood tests and relevant clinical information.

Interactive Quiz

Use these five questions to check your understanding. Open each feedback panel after choosing an answer.

Q1. What is the main clinical use of ALT?
Assessment of hepatocellular injury patternDiagnosis of anaemiaMeasurement of renal filtrationCoagulation screening
Reveal feedback

Correct answer: assessment of hepatocellular injury pattern. ALT is interpreted with other liver tests and clinical context.

Q2. Why does absorbance fall in the ALT assay?
NADH is oxidised to NAD+Albumin is precipitatedHaemoglobin is measured directlyBilirubin is converted to biliverdin
Reveal feedback

Correct answer: NADH is oxidised to NAD+. NADH absorbs at 340 nm, so its consumption causes absorbance to decrease.

Q3. What should happen before reporting patient ALT results?
QC and analyser flags should be acceptableReference intervals should be ignoredThe result should diagnose the patient aloneThe sample type no longer matters
Reveal feedback

Correct answer: QC and analyser flags should be acceptable. Analytical quality is essential before result release.

Q4. Which result pattern needs clinical context?
All ALT patternsOnly very high ALTOnly normal ALTOnly ALT below the interval
Reveal feedback

Correct answer: all ALT patterns. Even a normal ALT may need context if symptoms or risk factors are present.

Q5. Who authorises or technically validates results according to local laboratory rules?
Biomedical Scientist / authorised laboratory staffThe patientThe courierThe website
Reveal feedback

Correct answer: Biomedical Scientists or authorised laboratory staff review results according to local governance.

References and Further Reading

  1. Abbott Diagnostics. Alinity c Alanine Aminotransferase assay Instructions for Use. Use the current assay document for analyser-specific requirements.
  2. Rifai N, Horvath AR, Wittwer CT, editors. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023.
  3. McPherson RA, Pincus MR, editors. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021.
  4. Newsome PN, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67:6–19.
  5. ISO 15189:2022. Medical laboratories — Requirements for quality and competence.
  6. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

Educational use

This resource is intended for education and professional development. Laboratory methods, reference intervals, specimen requirements and analytical limitations may vary between laboratories and analytical systems. Always follow current manufacturer documentation, locally validated procedures and relevant professional guidance. This page is not intended to provide individual medical diagnosis or treatment advice.